Eptifibatide provides additional platelet inhibition in NonST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel
Results of the platelet activity extinction in NonQ-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study
Miles Dalby, MD*,
Gilles Montalescot, MD, PhD*,*,
Claire Bal dit Sollier, MD ,
Eric Vicaut, MD, PhD ,
Thierry Soulat, MD ,
Jean-Philippe Collet, MD, PhD*,
Rémi Choussat, MD*,
Vanessa Gallois, MSc*,
Gérard Drobinski, MD, PhD*,
Ludovic Drouet, MD and
Daniel Thomas, MD*
* Institut de Cardiologie, Pitié-Salpétrière University Hospital, Paris, France
Department of Haematology, Hospital Lariboisiere, Paris, France
Unite de Recherche Clinique, Hospital Lariboisiere, Paris, France

View larger version (37K):
[in a new window]
|
Figure 1 Charts of conformationally active glycoprotein IIb/IIIa receptor expression (PAC-1) and anti-fibrinogen (Fg) before clopidogrel administration (T1), >2 h after clopidogrel (T2), and during eptifibatide infusion (T3). Receptor expression and Fg binding are expressed on the y axis as the mean number of sites expressed per platelet. ADP = adenosine diphosphate.
|
|

View larger version (48K):
[in a new window]
|
Figure 2 Charts of total glycoprotein IIb/IIIa receptor expression (P2) and P-selectin expression before clopidogrel administration (T1), >2 h after clopidogrel (T2), and during eptifibatide infusion (T3). Receptor expression and fibrinogen binding are expressed on the y axis as the mean number of sites expressed per platelet. "ns" is indicated in parenthesis for p values <0.05 but >0.0036 and therefore are not significant after Bonferonni correction. ADP = adenosine diphosphate.
|
|

View larger version (35K):
[in a new window]
|
Figure 3 Charts of platelet microparticle count as a function of blood volume (MPV) (top panel) and platelet count (MPP) (bottom panel) on the y axis before clopidogrel administration (T1), >2 h after clopidogrel (T2), and during eptifibatide infusion (T3).
|
|
|